Clinical Study Results, Acquisitions, Joint Ventures and Awards for Contributions to the Technology Industry - Research Report

     Clinical Study Results, Acquisitions, Joint Ventures and Awards for
   Contributions to the Technology Industry - Research Report on Medtronic,
            Edwards Lifesciences, Opko, LifePoint, and Allscripts

PR Newswire

NEW YORK, September 11, 2013

NEW YORK, September 11, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Medtronic,
Inc. (NYSE: MDT), Edwards Lifesciences Corp. (NYSE: EW), Opko Health, Inc.
(NYSE: OPK), LifePoint Hospitals Inc. (NASDAQ: LPNT), and Allscripts
Healthcare Solutions, Inc. (NASDAQ: MDRX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Medtronic, Inc. Research Report

On September 3, 2013, Medtronic Inc. (Medtronic) announced the final
three-year results from Symplicity HTN-1, the first and longest running
clinical study investigating the safety and efficacy of renal denervation.
According to the Company, 88 patients were available for the 36 month
evaluation following the treatment with the Symplicity(TM) renal denervation
system. Medtronic reported that the patients demonstrated sustained reductions
in blood pressure year-over-year and approximately 50% of the patients
achieved goal of a systolic blood pressure <140 mm Hg despite having a mean
systolic blood pressure of 169.8 mm Hg pre-denervation. Professor Henry Krum,
Principal Investigator of Symplicity HTN-1 and Chair of Medical Therapeutics,
Professor of Medicine and Director of the Monash Centre of Cardiovascular
Research and Education in Therapeutics, Melbourne, Australia said, "Achieving
goal of below 140 mm Hg in about half of these patients is impressive
considering that these patients had very high baseline blood pressures despite
being on multiple pharmaceutical agents." The Full Research Report on
Medtronic, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Edwards Lifesciences Corp. Research Report

On September 3, 2013, Edwards Lifesciences Corp. (Edwards Lifesciences)
announced that a new post-hoc data analysis from the PARTNER Trial showed that
diabetic patients with aortic stenosis in need of heart valve replacement, but
at high surgical risk, experienced a 35% lower all-cause mortality one year
after treatment with transcatheter aortic valve replacement (TAVR), as
compared to those treated with surgical aortic valve replacement. In the
analysis of diabetic patients in the as-treated high-risk cohort of The
PARTNER Trial, the Company reported that one-year all-cause mortality was 18%
for patients treated with the Edwards SAPIEN valve delivered via the femoral
artery or a small incision between the ribs. Additionally, the analysis showed
that diabetic patients treated with TAVR experienced quicker quality of life
improvement and lower one-year rates of renal failure than those treated with
surgery. The Full Research Report on Edwards Lifesciences Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


Opko Health, Inc. Research Report

On August 29, 2013, OPKO Health Inc. (OPKO) announced the completion of its
acquisition of PROLOR Biotech Inc. (PROLOR). Pursuant to the acquisition,
PROLOR stockholders will receive 0.9951 shares of OPKO common stock for each
share of PROLOR common stock. "We are pleased to complete the acquisition of
PROLOR and broaden our portfolio of market-transforming therapies in selected
specialty markets," commented Dr. Phillip Frost, OPKO's Chairman and CEO.
"PROLOR's drug product candidates for growth hormone deficiency, hemophilia,
obesity and diabetes, along with its broadly applicable technology platforms
and efficient research and development center, are highly valuable assets that
complement OPKO's growth strategy." The Full Research Report on Opko Health,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:


LifePoint Hospitals Inc. Research Report

On September 4, 2013, LifePoint Hospitals Inc. (LifePoint) announced that it
has signed a definitive agreement with the Fauquier Health Board of Directors
to form a joint venture to jointly own and operate Fauquier Health. Under the
terms of the agreement, LifePoint will own 80% of the joint venture while
Fauquier Health and the Warrenton community would retain 20% of the ownership
stake. LifePoint Chairman and CEO William F. Carpenter III said, "We have
enjoyed learning more about Fauquier Health and working with the Fauquier
board and leadership team to reach this agreement for the proposed joint
venture. We are excited about the opportunities for us to work together to
enhance healthcare in this region." The Full Research Report on LifePoint
Hospitals Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Allscripts Healthcare Solutions, Inc. Research Report

On September 6, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts)
announced that Baylor Health Care System has been the recipient of the 2013
Tech Titans Technology Adopter Award for its successful design and
implementation of innovations enabled by Allscripts Open Solutions platform.
According to Allscripts, the award recognizes companies and individuals who
have made outstanding contributions to the technology industry and to the
technology industry in North Texas. The Company informed that several custom
components for its Sunrise Clinical Manager were developed by Baylor to
improve the adoption and use of Computerized Physician Order Entry (CPOE) and
the use of electronic physician documentation. Paul M. Black, President and
CEO of Allscripts congratulated Baylor for this special recognition. The Full
Research Report on Allscripts Healthcare Solutions, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner

Contact: Joe Thomas; Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.